

Special Issue

Biomarkers of Thyroid Cancer

Message from the Guest Editors

Thyroid cancer is a heterogeneous disease comprised of various molecular and histologic subtypes. Its diverse clinical outcomes highlight the need for identifying robust biomarkers of practical relevance. Biomarkers provide useful information in guiding clinical decision making in patients with thyroid cancer. Biomarkers can be biomolecules such as DNA, RNA, protein, peptide, and biomolecule chemical modifications, or characteristics that can be measured through clinical, pathological, or radiological findings. Biomarkers for thyroid cancer patients are used in research and clinical practice for: - Diagnosing thyroid nodules and thyroid cancer; - Predicting outcomes of thyroid cancer; - Including responses to specific therapeutic interventions; - Targeting specific groups of patients for whom a particular drug may be useful. This Special Issue of *Cancers* is aimed at presenting the latest research on the diagnostic, prognostic, and theranostic biomarkers of thyroid cancer, as well as the application of biomarkers in clinical trials.

Guest Editors

Prof. Dr. Chan-Kwon Jung

Department of Pathology, Seoul St. Mary's Hospital, The Catholic University, Seoul 06591, Republic of Korea

Dr. Andrey Bychkov

Department of Pathology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan

Deadline for manuscript submissions

closed (15 December 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/33717

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)